Eversept Partners LP Sells 185,151 Shares of Natera, Inc. $NTRA

Eversept Partners LP cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 35.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 334,493 shares of the medical research company’s stock after selling 185,151 shares during the quarter. Natera makes up approximately 3.9% of Eversept Partners LP’s portfolio, making the stock its 5th largest holding. Eversept Partners LP’s holdings in Natera were worth $76,629,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. Capital Impact Advisors LLC grew its position in shares of Natera by 174.5% in the fourth quarter. Capital Impact Advisors LLC now owns 178,567 shares of the medical research company’s stock valued at $40,908,000 after purchasing an additional 113,508 shares during the last quarter. Caption Management LLC acquired a new stake in shares of Natera in the fourth quarter valued at approximately $2,749,000. Castle Hook Partners LP grew its position in shares of Natera by 24.1% in the fourth quarter. Castle Hook Partners LP now owns 2,167,869 shares of the medical research company’s stock valued at $496,637,000 after purchasing an additional 420,621 shares during the last quarter. Cinctive Capital Management LP acquired a new stake in shares of Natera in the fourth quarter valued at approximately $1,107,000. Finally, American Trust acquired a new stake in shares of Natera in the fourth quarter valued at approximately $296,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have commented on NTRA shares. The Goldman Sachs Group started coverage on shares of Natera in a research note on Friday, June 5th. They issued a “neutral” rating and a $245.00 target price for the company. Wolfe Research started coverage on shares of Natera in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $260.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $249.00 target price on shares of Natera in a research note on Tuesday, May 12th. William Blair started coverage on shares of Natera in a research note on Tuesday, April 14th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. lifted their target price on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $256.53.

Insider Buying and Selling

In other Natera news, CFO Michael Burkes Brophy sold 3,070 shares of Natera stock in a transaction on Wednesday, April 29th. The shares were sold at an average price of $193.74, for a total value of $594,781.80. Following the transaction, the chief financial officer owned 58,291 shares in the company, valued at $11,293,298.34. This trade represents a 5.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction on Friday, June 5th. The shares were sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares in the company, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 162,342 shares of company stock worth $35,283,396 over the last 90 days. Company insiders own 5.05% of the company’s stock.

Natera Stock Up 2.9%

Shares of NTRA opened at $226.44 on Thursday. The firm has a market cap of $32.43 billion, a PE ratio of -138.92 and a beta of 1.56. The company’s fifty day moving average is $207.35 and its two-hundred day moving average is $215.50. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.